持续释放的西塔利普丁微针用于通过纤维细胞转化为脂肪细胞的痕预防
Ju-Lei Zhang1,2, Jun-Nian Zhou2, Chao Tang2
1Department of Plastic and Reconstructive Surgery The First Medical Centre Chinese PLA General Hospital 28 Fuxing Street Beijing 100853 China.
Small science
|December 15, 2025
概括
抗糖尿病药物西塔格利普丁通过重编程纤维细胞变成脂肪细胞来防止痕形成. 这种新的方法使用细胞命运调节来改善伤口愈合和痕治疗.
科学领域:
- 再生医学是一种再生医学.
- 皮肤病学 皮肤病学
- 细胞生物学 细胞生物学
背景情况:
- 病理性痕治疗需要新的,安全和有效的方法.
- 细胞命运调节为组织再生和疾病治疗提供了潜力.
- 纤维细胞亚型,如二二酶IV (DPP4) 阳性细胞,与皮肤纤维化有关.
研究的目的:
- 调查西塔利普丁是否通过抑制DPP4,可以将纤维细胞转向脂肪生成系,以防止痕形成.
- 通过细胞命运调节探索西塔利普丁在痕治疗中的治疗潜力.
主要方法:
- 隔离和表征基洛因衍生的介质干细胞 (KMSCs).
- 在DPP4阳性和DPP4阴性KMSC中评估脂肪生成和纤维化潜力.
- 通过IGF1信号传递对西塔格利普丁对脂肪生成的影响的评估.
- 开发用于体内研究的含有西塔利普丁的微针贴片.
主要成果:
- DPP4阴性KMSC显示增强的脂肪生成潜力,而DPP4阳性KMSC显示出更大的纤维化潜力.
- 西塔利普丁通过抑制DPP4介导的IGF1截断来促进KMSC中的脂肪生成,从而增强IGF1信号传递.
- 含有西塔格利普丁的微针贴片通过促进纤维细胞转化为脂肪细胞,有效地减少了体内痕的形成.
结论:
- 西塔格利普丁可以通过调节纤维细胞细胞命运向脂肪生成而防止痕形成.
- 这项研究提出了西塔格利普丁在治疗伤口愈合期间的痕形成方面的一种新应用.
- 这些发现推动了通过细胞命运调节来治疗病理性痕的临床策略.
相关概念视频
01:19Clinical Applications of Epidermal Stem Cells
3.2K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.2K
01:23Dipeptidyl Peptidase 4 Inhibitors
557
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
557
01:06Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
01:24Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818